Options sequential therapy in prostate cancer patients

01/2017

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno

SUMMARY

During past years, there was a significant progress in the threatment of metastatic castration-resistant prostate cancer. We have various drugs available, including those affecting androgenic receptor - enzalutamide and abiraterone, imunotherapeuthic agents - sipuleucel-T, from taxan-based chemotherapeutics we administer docetaxel and cabazitaxel and as a bone tissue targeting radiopharmaceutical, radium-223 is used. Sequentional threatment allow us to significantly prolong the survival of the patients suffering from metastatic castration-resistant prostate cancer.

KEY WORDS

metastatic castration-resistant prostate cancer, abiraterone, enzalutamide, sipuleucel-T, docetaxel, cabazitaxel, radium-223, pre-chemoindication, post-chemoindication